News & Updates

CUHK introduces new modular robot-assisted system for radical prostatectomy

26 Jul 2023 by

Urological surgeons from the Chinese University of Hong Kong (CUHK) have become the first in the Greater China region to perform radical prostatectomy with a new modular robot-assisted system, enhancing accessibility and mobility of robotic surgery across operative theatres (OTs).

CUHK introduces new modular robot-assisted system for radical prostatectomy

26 Jul 2023

Redefining survival in 3L+ large B-cell lymphoma with axicabtagene ciloleucel

26 Jul 2023 by

Singapore’s Health Sciences Authority recently approved axicabtagene ciloleucel (Yescarta) for the treatment of relapsed or refractory large B-cell lymphoma (LBCL) in adults after ≥2 lines of systemic therapy. Shedding light on this innovative therapy, Dr Matthew Frank, Assistant Professor of Medicine specializing in Blood and Marrow Transplantation and Cellular Therapy at Stanford University, Stanford, California, US, discussed landmark trial data, some real-world evidence, and their implications for patient selection and adverse event management during the Yescarta Commercial Launch in Singapore in May.

Redefining survival in 3L+ large B-cell lymphoma with axicabtagene ciloleucel

26 Jul 2023

SG data: Booster mRNA vax shots shield cancer-affected individuals from COVID-19

25 Jul 2023 by

Administration of booster doses of mRNA-based vaccines provide protection against COVID-19 and its adverse outcomes in patients with cancer who are actively receiving treatment as well as in cancer survivors, as shown in a study from Singapore.

SG data: Booster mRNA vax shots shield cancer-affected individuals from COVID-19

25 Jul 2023

Gilteritinib as post-HCT maintenance for FLT3-ITD AML: Yay or nay?

25 Jul 2023 by

The BMT CTN* 1506 (MORPHO) trial narrowly missed its primary outcome, but it did show that the potent oral FLT3 inhibitor gilteritinib conferred benefit for a subset of individuals with FLT3-ITD** acute myeloid leukaemia (AML).

Gilteritinib as post-HCT maintenance for FLT3-ITD AML: Yay or nay?

25 Jul 2023

Benefits of 1L ribociclib extend across MONALEESA studies

22 Jul 2023 by

First-line (1L) treatment with the CDK4/6 inhibitor ribociclib plus endocrine therapy (RIB + ET) confers consistent benefits in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer in the pooled analysis of the MONALEESA-2, -3, and -7 studies presented at the San Antonio Breast Cancer Symposium (SABCS) 2022.

Benefits of 1L ribociclib extend across MONALEESA studies

22 Jul 2023

Age, tumour size predict post-TACE complications in HCC patients

21 Jul 2023 by

In patients with hepatocellular carcinoma (HCC), most complications following transarterial chemoembolization (TACE) involve minor postembolization syndrome, reveals a study presented at EASL 2023. The incidence of major complications is high at 25 percent, with a 1.8-percent death rate.

Age, tumour size predict post-TACE complications in HCC patients

21 Jul 2023

Conjugated estrogens/bazedoxifene use tied to higher rates of endometrial cancer, hyperplasia

21 Jul 2023

In the first years of use, conjugated estrogens/bazedoxifene (CE/BZA) appears to be associated with slightly higher rates of endometrial cancer and endometrial hyperplasia compared with estrogen/progestin (EP) combination hormone therapy, according to a study.

Conjugated estrogens/bazedoxifene use tied to higher rates of endometrial cancer, hyperplasia

21 Jul 2023

S-ITM lesions predict relapse in cutaneous SCC

19 Jul 2023

In patients with cutaneous squamous cell carcinoma (cSCC) presenting with satellitosis or in-transit metastasis (S-ITM), the size and the number of S-ITM lesions are associated with a higher risk of relapse, while the number of S-ITM confers an increased risk of specific death, reveals a study.

S-ITM lesions predict relapse in cutaneous SCC

19 Jul 2023

Luspatercept bests epoetin alfa in head-to-head LR–MDS-related anaemia trial

17 Jul 2023 by

In the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (LR-MDS), luspatercept seems to perform better than epoetin alfa at restoring iron stores, according to the interim results of the open-label phase III COMMANDS trial.

Luspatercept bests epoetin alfa in head-to-head LR–MDS-related anaemia trial

17 Jul 2023

Does the type of facility affect outcomes in patients with Merkel cell carcinoma?

17 Jul 2023

Treatment of Merkel cell carcinoma (MCC), a rare neuroendocrine skin cancer with high mortality and rising incidence, at either an academic or a high-volume centre tends to lead to better patient survival, as shown in a recent study.

Does the type of facility affect outcomes in patients with Merkel cell carcinoma?

17 Jul 2023

News & Updates

Filter by Specialty:

Specialty:

CUHK introduces new modular robot-assisted system for radical prostatectomy

CUHK introduces new modular robot-assisted system for radical prostatectomy

Redefining survival in 3L+ large B-cell lymphoma with axicabtagene ciloleucel

Redefining survival in 3L+ large B-cell lymphoma with axicabtagene ciloleucel

SG data: Booster mRNA vax shots shield cancer-affected individuals from COVID-19

SG data: Booster mRNA vax shots shield cancer-affected individuals from COVID-19

Gilteritinib as post-HCT maintenance for FLT3-ITD AML: Yay or nay?

Gilteritinib as post-HCT maintenance for FLT3-ITD AML: Yay or nay?

Benefits of 1L ribociclib extend across MONALEESA studies

Benefits of 1L ribociclib extend across MONALEESA studies

Age, tumour size predict post-TACE complications in HCC patients

Age, tumour size predict post-TACE complications in HCC patients

Conjugated estrogens/bazedoxifene use tied to higher rates of endometrial cancer, hyperplasia

Conjugated estrogens/bazedoxifene use tied to higher rates of endometrial cancer, hyperplasia

S-ITM lesions predict relapse in cutaneous SCC

S-ITM lesions predict relapse in cutaneous SCC

Luspatercept bests epoetin alfa in head-to-head LR–MDS-related anaemia trial

Luspatercept bests epoetin alfa in head-to-head LR–MDS-related anaemia trial

Does the type of facility affect outcomes in patients with Merkel cell carcinoma?

Does the type of facility affect outcomes in patients with Merkel cell carcinoma?